Dyne Therapeutics (DYN) Projected to Post Quarterly Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Dyne Therapeutics Price Performance

DYN stock traded down $0.05 during mid-day trading on Friday, hitting $11.06. 1,568,408 shares of the stock were exchanged, compared to its average volume of 1,535,397. The business has a fifty day moving average price of $10.79 and a 200 day moving average price of $19.63. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $47.45. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.11 and a beta of 1.21.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Finally, Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last three months. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.